A Phase 1 Study for the Evaluation of Excretion (Mass Balance) and Pharmacokinetics of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Poziotinib (Primary)
- Indications Cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Spectrum Pharmaceuticals
- 07 Nov 2019 According to a Spectrum Pharmaceuticals media release, first patient in this trial was enrolled at The University of Texas MD Anderson Cancer Center.
- 25 Jul 2019 Planned End Date changed from 1 Mar 2020 to 1 Jun 2020.
- 25 Jul 2019 Status changed from not yet recruiting to recruiting.